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Abstract
The molecular docking of tamoxifen’s metabolites, 4-hydroxy-tamoxifen, N-desmethyl-
tamoxifen, and 4-hydroxy-N-desmethyl-tamoxifen, in estrogen and progesterone hor-
mone receptors was studied in aqueous solution. The metabolites 4-hydroxy-tamoxifen,
N-desmethyl-tamoxifen, and 4-hydroxy-N-desmethyl-tamoxifen exhibit a binding energy
in the estrogen receptor cavity of 10.69 kcal/mol, 10.9 kcal/mol, and 11.35 kcal/mol,
respectively, and 1.45 kcal/mol, 9.29 kcal/mol, and 0.38 kcal/mol in the progesterone
receptor. This indicates a spontaneous interaction between the metabolites and the active
sites in the hormone receptors. Docking has an adequate accuracy for both receptors, and
from this calculation the active site residues were defined for the different metabolites and
the estrogen and progesterone receptors. Also, the chemical reactivity of the amino acids
of the active sites of each metabolite was determined. These reactivity properties were
obtained within the framework of density functional theory, using the functional M06
with the basis set 6-31G (d). The results indicate that in the estrogen receptor, the highest
charge transfer of the three analyzed metabolites is in the union of the metabolite and the
Leu346-Thr347 residue. The progesterone receptor shows minor tendency to react with
higher hardness values than the estrogen receptor. The hydrogen bonds are three for the
estrogen receptor in two different metabolites, while in progesterone only one is formed
with the N-desmethyl-tamoxifen metabolite.
Keywords:molecular docking, tamoxifen, binding energy, charge transfer, hydrogen
bond, hormone receptors
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1. Introduction
Breast cancer is the leading cause of cancer death in women. A prognosis of breast cancer can
be issued because there are parameters that predict the evolution or aggressiveness of the
cancer, such as lymph nodes, tumor size, and histological grade of cancer [1–4]. In mammary
cells there are hormone receptors (estrogen receptors (ERs) and progesterone receptors
(PRs)) that function as “switches,” activating or deactivating a particular function in the
mammary cell.
Over the last two years a number of drugs have been developed with specific properties for
the treatment of breast cancer. Fulvestrant is a steroid-based selective estrogen receptor
downregulator (SERD) that antagonizes and degrades ER-α and is active in patients who
have progressed to antihormonal agents [5]. Also, the selective ER modulators (SERMs)/SERD
hybrids (SSHs) have been used to facilitate the first-line treatment for ER 1 degradation in
breast cancer cells [6].
Another important piece of research by Srinivasan et al. presents the discovery of a series of
SERDs lacking a prototypical side chain. This absence improves the mechanism called “indi-
rect antagonism” [7]. The latest developments have found the optimal design of antiestrogen
cores and side chains with the middle structures of the original SERMs class, such as tamoxifen
(TAM), raloxifene, lasofoxifene, and bazedoxifene. Also, current studies of SERDs have been
made by GlaxoSmithKline(GSK), Genentech, and AstraZeneca. In these studies the side chain
is modified to a simple adamantyl core [8].
In addition, for several years, have been used antibodies as cancer drugs, and some examples are
trastuzumab and pertuzumab, which are used in breast cancer as the only component. In fact,
efforts have been made to use the antibodies conjugated with a variety of substances with the
aim of improving their effect. Research on cancer therapy is still in progress [9].
TAM is a SERM [10, 11] and is used for the treatment of hormone receptors expressing breast
cancer [12]. This drug is metabolized in the liver, producing three different metabolites:
4-hydroxy-tamoxifen (4OHTAM), N-desmethyl-tamoxifen (NDTAM), and 4-hydroxy-N-desmethyl-
tamoxifen, also known as endoxifen (END) [13, 14]. These metabolites show a range of agonist
and partial antagonist activities of ER-mediated effects [15]. In vivo studies have shown that
TAM competes against estrogens to dock to the receptors, resulting in an attenuation of the
cellular response measured by estrogen [16]. Therefore, the clinical response to TAM therapy
will depend on the total effect of the resulting metabolites on the patient, their affinity for
receptors, and their agonist/antagonist profile [15].
Recently, a number of theoretical studies on TAM and some of its active metabolites have
described its interaction with ERs. Calculations of molecular dynamics have been used to
model dynamic fluctuations in structures of ERs (ER-α following the binding to estradiol and
the metabolite 4OHTAM) [17]. Recently, in an article written by the authors, the molecular
docking of TAM in ER and PR was presented in which the active site of the hormone receptors
was determined, as well as the charge transfer of the drug to the amino acids of the active sites
of the receptors [18]. Other theoretical studies analyzed the chirality of TAM using density
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functional theory (DFT) with functional B3LYP and BLYP with a basis set 6-311++G(2d, 2p)
[12]. In addition, there was a reported analysis of the amount of charge transfer and the
direction of the flow of charge of alkylating drugs in the presence of DNA bases allowing
prediction among its bases of which one is the main target of these antitumor drugs [19].
Another technique is molecular docking, which is a computational procedure that attempts to
predict noncovalent binding of macromolecules (receptor) and small molecules (ligands) effi-
ciently [20]. In detail, docking consists of an operation in which one molecule is brought into
the vicinity of another while calculating the interaction energies of the many mutual orienta-
tions and conformations of the two interacting species. A docking procedure is used as a guide
to identify the preferred orientation of one molecule relative to the other [21]. This method
plays a key role in promoting fundamental biomolecular events such as enzyme–substrate,
drug–protein, and drug–nucleic acid interactions [22]; it is also widely used in drug design [23].
Some authors have used the molecular docking of macromolecules to define the energy and
bonding affinity in ER-α and ER-β with estrogen [24]. It has also been used in the analysis of a
maltogenic amylase of Bacillus lehensis G1, which provides a view of the substrate and speci-
ficity in the macromolecule [25], and in the DNA docking analysis of natural products such as
methyltransferase inhibitors, which have become an alternative for cancer therapies [26].
The objective of this research is to develop molecular docking of the metabolites of TAM
with the macromolecules ER and PR, to obtain an active site of the hormone receptors. To
perform computational protein–ligand docking experiments, a 3-D structure of the target
protein at atomic resolution must be available. The most reliable sources are crystal and
solution structures provided by the Protein Data Bank (PDB) [26, 27]. The hormone recep-
tors selected for this work are the 1A52 ER-α ligand-binding domain complexed to estradiol,
and the 1A28 hormone-bound human progesterone receptor ligand-binding domain. Both
belong to the organism Homo sapiens and are present in breast cancer cells. Molecular
docking has the advantage of working on a large scale, as well as determining the important
sites of the macromolecule (active sites) [27, 28]. Once the active site is defined, an accurate
calculation of electronic structure can be developed with methods such as DFT, which is the
most popular, efficient, and versatile tool for obtaining precise information of molecular
systems. For both receptors, the amino acids (residues) forming the active site were ana-
lyzed in an attempt to obtain their electronic properties such as ionization potential, electron
affinity, electrophilicity, chemical hardness, chemical potential, and electronegativity. A
transfer and charge flow direction analysis was also performed.
2. Computational details
2.1. Molecular docking
Molecular docking is calculated with the specially tailored software AutoDock 4.2 with the
Lamarckian Genetic Algorithm (LGA) [28, 29] to explore how ER and PR bond with the metab-
olites. AutoDock uses a semiempirical free energy force field to predict binding free energies of
A Combined Molecular Docking and Electronic Structure Study for a Breast Cancer Drug Design
http://dx.doi.org/10.5772/intechopen.72895
117
small molecules to macromolecule targets [29]. The force field is based on a comprehensive
thermodynamic model that allows incorporation of intramolecular energies into the predicted
free energy of binding. It also incorporates a charge-based method for evaluation of desolvation
designed to use a typical set of atom types [30]. The use of LGA allows individual conformations
to search their local conformational space, find local minima, and then pass this information to
later generations [29]; also LGA can handle ligands with more degrees of freedom and is
efficient, reliable, and successful [31].
The water molecules in the receivers are eliminated and only the polar H atoms are added. The
docking area is selected by constructing a grid box, size 52  36  34 points, centered at x, y,
and z coordinates of 89.304, 14.745, and 70.512, respectively, for ER, and a grid box, size 20 
18  26 points, centered at x, y, and z coordinates of 36.999, 31.767, and 42.694, respectively, for
PR using in both receptors a grid spacing of 0.375 Å in AutoGrid [28, 29]. The docking
parameters used for the LGA-based conformational searches are: docking trials—150; popula-
tion size—150; maximum number of energy evaluations—25,000,000; maximum number of
top individuals to survive to next generation—1; rate of gene mutation—0.02; rate of crossover
—0.8; mean of Cauchy distribution for gene mutation—0.0; variance of Cauchy distribution for
gene mutation—1.0; and number of generations for picking the worst individual—10.
2.2. Electronic structure calculations
The energy calculations of the amino acids that make up the active site on ER, PR, and TAM
metabolites are calculated with the functional hybrid meta-GGAM06 [32, 33] developed by the
Truhlar Group from the University of Minnesota, combined with the basis set 6-31G (d)
proposed by Pople [34] and the conductor-like polarizable continuum model (CPCM) [35]
using water as a solvent. All calculations were made using DFT [35–38] with the Gaussian
program 09 [39]. The charge distribution for amino acids and metabolites was obtained with
the population analysis of Hirshfeld charges [40].
Equations
η ¼
ðI  AEÞ
2
(1)
χ ¼
ðI þ AEÞ
2
(2)
ω ¼
μ2
2η
(3)
μ ¼ χ (4)
ΔN ¼
μ
B
 μ
A
2ðη
A
þ η
B
Þ
(5)
Table 1. Global reactivity and charge transfer parameters.
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The chemical reactivity descriptors of the studied molecular systems were calculated using the
DFT conceptual framework. These parameters include ionization potential (I), electron affinity
(EA), chemical hardness (η) [41], electronegativity (χ) [41], electrophilicity (ω) [42], and chem-
ical potential (μ) [42]. The overall interaction between metabolites and the amino acids that
make up the active site on ER and PR can be identified by the charge transfer. This parameter
determines the behavior of the different molecular systems as a donor or as an acceptor
system. In this case, the electrons transferred from the metabolites to the amino acids of the
active site of receptors or vice versa. The global interactions between two constituents can been
determined using the charge transfer parameter (∆N) [43].
The equations of the reactivity and charge transfer descriptors are shown in Table 1.
3. Results and discussion
3.1. Validation docking
Validation docking was performed for each hormone receptor using the PyMOL program [44].
Figure 1 shows the structure of the native co-crystallized TAM bond and its metabolites. The
root mean square deviation (RMSD) between TAM and the metabolites was calculated for each
Figure 1. Chemical structures of tamoxifen and metabolites.
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of the hormone receptor dockings. An RMSD value is considered a measurement of the
accuracy of the docking results. The optimal position is recognized if the RMSD value is less
than 2 Å [45]. In the case of metabolite dockings, TAM was used as the template for molecular
overlap, as it is known that this drug is metabolized into the metabolites analyzed in this
study. The metabolites were aligned by rotation and translation to obtain the RMSD using the
“Align” option in PyMOL. Therefore, the RMSD in ER obtained between TAMwith 4OHTAM,
END, and NDTAM is 0.672, 1.106, and 1.461, respectively. For PR the RMSD obtained between
TAM and 4OHTAM, END, and NDTAM is 1.387, 2.006, and 0.953, respectively. Figure 2 shows
the alignment between TAM (black) and 4OHTAM, END, and NDTAM (gray).
3.2. Analysis of the estrogen receptor with the metabolites
An analysis of molecular docking of the metabolites in ER was carried out, revealing the active
site of the ER, followed by its description, the analysis of the chemical reactivity parameters of
the residues and the metabolites, as well as the description of the hydrogen bonds between the
metabolites and the ER active site.
Figure 2. Conformation of tamoxifen and metabolites after docking in hormone receptors.
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3.2.1. Molecular docking
The binding energy of the metabolites with the ER active site was predicted with molecular
docking calculations. The negative value of the binding energy (affinity) in the docking indi-
cates that the system is stable and that there is an interaction between ER and the metabolites
in the active site: 10.69 kcal/mol for 4OHTAM, 11.35 kcal/mol for END, and  10.90 kcal/
mol for NDTAM. It was observed that the binding affinity was lower in 4OHTAM; this is due
to the effect of the orientation of the metabolite within the active site caused by the influence of
the tertiary amine functional group containing the 4OHTAM.
Finally, the binding energy shows that END, which exhibits 11.35 kcal/mol, is the metabolite
with the highest affinity with the active site. It even shows a better affinity than TAM at 10.38
kcal/mol [18]. This coincides with previous information reported by Clarke [46] who says that
END has an affinity for ERs higher than NDTAM or TAM itself. As can be observed, all the
metabolites have a high affinity to the receptor. According with Gareth [47], the greater the
affinity of the ligand for the receptor, the more easily it binds to that receptor. This is important
because the binding of a drug to a receptor stimulates the physiological response that charac-
terizes the action of the drug, which means that release of a series of biochemical events results
in a biological or pharmacological effect [47].
The schematic structure of the active site and the binding energies are shown in Figure 3.
3.2.2. Active site
The conformational coupling of the active site with each metabolite is described below.
4OHTAM. There are 14 residues in contact with the metabolite 4OHTAM at the active site of the
ER. Nine of them are linked forming an amino acids sequence: leucine346-threonine347 (Leu346-
Thr347), tryptophan383-leucine384 (Trp383-Leu384), glutamic acid353-leucine354 (Glu353-
Leu354), and leucine349-alanine350-aspartic acid351 (Leu349-Ala350-Asp351). The other five
are: glycine residue (Gly521)—glycine is the smallest of the amino acids. It is ambivalent, which
means that the amino acid can be inside or outside of the protein molecule; lysine529 (Lys529)—
this residue contains a protonated amino group that provides a positive charge to proteins as
acetyltransferases; histidine524 (His524)—this residue has a positively charged imidazole func-
tional group. This group participates in enzyme-catalyzed reactions; phenylalanine404 (Phe404)
—an essential amino acid, it is a derivative of alanine with a phenyl substituent on the β carbon.
Due to its hydrophobicity, phenylalanine is nearly always found buried within a protein. The pi
electrons of the phenyl ring can stack with other aromatic systems and often do so within folded
proteins, adding stability to the structure; and finally, methionine388 (Met 388), which has a
hydrophobic thiol ether in its lateral chain. According to the results obtained by theoretical
calculations, in the metabolite 4OHTAM the active site of estrogen coincides with that reported
by Shiau et al. [48].
END. The active site of END is formed by the following residues: leucine346-threonine347 (Leu346-
Thr347), leucine387-methionine388 (Leu387-Met388), tryptophan383-leucine384 (Trp383-Leu384),
glycine521 (Gly521), and histidine524 (His524). The last two residues are highly hydrophilic.
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NDTAM. The active site in NDTAM consists of the following residues: leucine346-threo-
nine347 (Leu346-Thr347), histidine524-leucine525 (His524-Leu525), tryptophan383-leucine384
(Trp383-Leu384), and (Leu349-Ala350-Asp351),and hydrophilic residue glycine521 (Gly521)
and hydrophobic residues phenylalanine404 (Phe404), glutamic acid (Glu353), and leucine428
(Leu428).
Most of the residues are situated over the planar core of the ligand. The others surround the
functional groups amine and hydroxyl. These interactions contribute to binding energies of up
to 10 kcal/mol.
The metabolites act by blocking the activation domain AF-2 of ER found in the ligand bond
domain or LBD of the active site. Therefore, the metabolites act as estrogen antagonists over
the genes that require only the activation domain AF-2 [49, 50].
The residues for the metabolites in ER are shown in Figure 3.
Figure 3. Amino acids of the active site of the estrogen receptor with (A) 4OHTAM, (B) END, and (C) NDTAM.
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3.2.3. Chemical reactivity
Once the most stable structure of the active site of TAM’s metabolites were defined, an analysis
of the reactivity of ER residues was performed using descriptors such as ionization potential
(I), electron affinity (EA), chemical potential (μ), chemical hardness (η), and electrophilicity (ω).
Calculated results for the reactivity parameters of the drug and residues of the ER are shown in
Table 2.
The electron affinities of the residues fluctuate from 0.21 eV to 0.91 eV. The highest value of
electron affinity is for the Trp383-Leu384 residue, which is present in the active site of the three
different metabolites analyzed in this work. According to the ionization potential results, the
residue with the greatest possibility of losing electrons is Leu346-Thr347 with 7.74 eV. This
residue is present in the active site of the three metabolites.
Metabolite Active site EA (eV) I (eV) hη(eV) μ = –χ (eV) ω (eV)
4OHTAM Gly521 0.21 7.03 3.41 3.62 1.92
Met388 0.46 6.11 2.82 2.39 1.91
His524 0.43 6.2 2.89 3.31 1.9
Lys529 0.83 7.22 3.19 4.02 2.54
Phe404 0.51 6.4 2.95 3.46 2.03
Trp383-Leu384 0.91 6.04 2.56 3.47 2.35
Glu353-Leu354 0.66 5.59 2.47 3.13 1.98
Leu346-Thr347 0.88 7.74 3.43 4.31 2.71
Leu349-Ala350-Asp351 0.73 5.79 2.53 3.26 2.1
END Gly521 0.21 7.03 3.41 3.62 1.92
His524 0.43 6.2 2.89 3.31 1.9
Leu387-Met388 0.51 6.25 2.87 3.38 1.99
Leu346-Thr347 0.88 7.74 3.43 4.31 2.71
Trp383-Leu384 0.91 5.79 2.53 3.26 2.1
NDTAM Gly521 0.21 7.03 3.41 3.62 1.92
Phe404 0.51 6.4 2.95 3.46 2.03
Glu353 0.2 5.62 2.71 2.91 1.57
Leu428 0.47 7 3.23 3.73 2.14
His524-Leu525 0.81 6.1 2.65 3.46 2.25
Trp383-Leu384 0.91 6.04 2.56 3.47 2.35
Leu346-Thr347 0.88 7.74 3.43 4.31 2.71
Leu349-Ala350-Asp351 0.73 5.79 2.53 3.26 2.1
Table 2. Parameters of chemical reactivity of the active site residues of the estrogen receptor.
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Chemical hardness ranges from 2.53 eV to 3.43 eV; this parameter measures the resistance to
change in the electronic configuration. The Glu353-Leu354 residue with 2.47 eV will react more
easily in the presence of 4OHTAM, the Leu349-Ala350-Asp351 residue with 2.53 eV will react
more easily in the presence of NDTAM, and the Trp383-Leu384 residue with 2.56 eV will react
more easily in the presence of END. The chemical potential (μ = χ) represents the average
effect between the tendency amongmolecules to attract and transfer electrons. This parameter is
an important part in the description of the charge transfer descriptor. The electronegativity
shows that the Leu346-Thr347 residue has the greatest tendency to attract electrons with 4.31
eV. This trend is repeated with the three different metabolites. Electrophilicity ω represents the
stabilization energy of the systems when it becomes saturated with electrons coming from the
surroundings. In this case, in the active site of 4OHTAM, value decreases in the following order:
Leu346-Thr347 > Lys529 > Trp383-Leu384 > Leu349-Ala350-Asp351 > Phe404 > Glu353-Leu354 >
Gly521 > Met388 > His524. In END the decreasing order is Leu346-Thr347 > Trp383-Leu384 >
Leu387-Met388 > Gly521 > His524 and in NDTAM the decreasing order is Leu346-Thr347 >
Trp383-Leu384 > His524-Leu525 > Leu428 > Leu349-Ala350-Asp351 > Phe404 > Gly521 > Glu353.
3.2.4. Charge transfer descriptor
The chemical reactivity descriptors mentioned above are intramolecular parameters, whose
values are calculated from the electronic properties of the molecule. To understand a chemical
reaction in depth an intermolecular parameter that represents the fractional number of elec-
trons transferred from one system to another should also be considered. This parameter is
called charge transfer and is described as Eq. 5 in Table 1. In this formula, μA is TAM’s
metabolites and μB is the chemical potential for the residues of the active site. ηA, ηB represent
the chemical hardness of TAM’s metabolites and its residues of the active site, respectively [43].
The significance of these kinds of interactions lies in the fact that they are the primary directors
of specificity, rate control, and reversibility in many biochemical reactions. Furthermore, it
represents a first step in understanding oxidative damage in the active site produced by the
TAM’s metabolites and leads to identify their functioning and biological activity. Some authors
use charge transfer to describe the oxidative damage of DNA bases [51, 52].
The interpretation of the value ∆N is as follows: for ∆N < 0 the charge flows from A to B (A acts
as an electron donor). For ∆N > 0 the charge flows from B to A (A acts as an electron acceptor).
Therefore, in the presence of Glu353-Leu354, Leu349-Ala350-Asp351, and His524 residues, ∆N
of 4OHTAM accepts electrons, while for the rest of the residues it acts as an electron donor.
END is an electron acceptor in the presence of the Trp383-Leu384 residue and with the
remainder of the residues it acts as an electron donor. Finally, NDTAM acts as an electron
acceptor in the presence of Glu353 and Leu349-Ala 350-Asp351 residues, and as an electron
donor with the remainder of the residues. The values are shown in Table 3.
The charge transfer descriptor is one of the noncovalent interactions that are present in biolog-
ical systems in a macromolecule–ligand complex. In this case, the highest charge transfer value
is in the same residue, Leu346-Thr347, for all the metabolites, which acts as a donor with
amounts of 0.080, 0.086, and –0.073 for 4OHTAM, END, and NDTAM, respectively. There-
fore, oxidative damage in the active site decreases in the order 4OHTAM > NDTAM > END.
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3.2.5. Electrostatics interactions
Other noncovalent interactions between the ligand and hormone receptor are the hydrogen
bond and pi–pi interactions. An analysis of these bonds between the ER and each of TAM’s
metabolites was done. The results are as follows.
4OHTAM. This residue has one hydrogen bond (C=O----O-H) between the donor group (O-H)
and the acceptor group (C=O) of the Gly521 residue. Also, there is a pi–pi interaction between
residue Trp383 and the planar core of the ligand.
END. There are two hydrogen bonds: first (C=O----OH) between the acceptor group (C=O) of
Gly521 and the donor group (O-H) belonging to one of the rings and second (C=O----HN)
between the accepting group (C=O) of Asp351 and the secondary amine (NH). The pi–pi
interaction was found among residue Trp383 and the planar core of the ligand.
Metabolite Residue ΔN
4OHTAM Gly521 0.022
Met388 0.089
His524 0.004
Lys529 0.058
Phe404 0.010
Trp383-Leu384 0.012
Glu353-Leu354 0.022
Leu346-Thr347 0.080
Leu349-Ala350-Asp351 0.009
NDTAM Gly521 0.016
Phe404 0.004
Glu353 0.047
Leu428 0.026
His524-Lue525 0.004
Trp383-Leu384 0.005
Leu346-Thr347 0.073
Leu349-Ala350-Asp351 0.015
END Gly521 0.029
His524 0.004
Leu387-Met388 0.010
Leu346-Thr347 0.086
Trp383-Leu384 0.001
Table 3. Charge transfer descriptor in the estrogen receptor.
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NDTAM. In this metabolite was found one hydrogen bond (C=O----HN) between the accepting
group (C=O) of Asp351 and the amine group of the ligand. No pi–pi interactions were found in
this ligand–receptor complex.
In all cases the metabolites analyzed followed the Lipinski et al. rule of five, which states: when
there are five or fewer hydrogen bonds the drug will not present poor absorption or perme-
ation and will be more active [53]. Figure 4 shows the metabolites as a ball and stick and the
residues of the active site as a tube. The hydrogen bonds are shown as green dots and pi–pi
interactions are the areas marked in yellow.
3.3. Analysis of the progesterone receptor with the metabolites
Analysis of molecular docking between PR and the metabolites is characterized by the active
site of PR: the active site was described and the calculation and analysis of chemical reactivity
Figure 4. Hydrogen bond (green) and pi–pi interactions (yellow) at the active site of the estrogen receptor with (A)
4OHTAM, (B) END, and (C) NDTAM.
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parameters of the residues and metabolites were carried out, as well as the description of the
hydrogen bond formed between the metabolites and the PR active site.
3.3.1. Molecular docking
The binding energy of TAM’s metabolites at the active site of PR has been predicted by
carrying out molecular docking calculations. The schematic structure of the active site and
the binding energies are shown in Figure 5. The negative value of the binding energy in the
Figure 5. Amino acids of the active site of the progesterone receptor with (A) 4OHTAM, (B) END, and (C) NDTAM.
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docking indicates that the system is stable and that there is an interaction between PR and
metabolites at the site: –1.45 kcal/mol for 4OHTAM, –0.38 kcal/mol for END, and –9.29 kcal/
mol for NDTAM.
Although the metabolites END and 4OHTAM have a negative bond energy, their values remain
very low compared to TAM, which has –9.38 kcal/mol [13]. Therefore, these two metabolites
will have very low biological activity in PRs.
3.3.2. Active site
The active site of PR obtained by theoretical analysis is as follows.
4OHTAM. There are 15 residues in contact with the metabolite 4OHTAM at the active site of
PR. Four of them are linked, forming an amino acids sequence, leucine718-aspartic acid719
(Leu718-Asn719) and leucine721-glycine722 (Leu721-Gly722). The other 11 residues are highly
hydrophilic: glutamine725 residue (Gln725), cysteine891 (Cys891), threonine894 (Thr894), and
phenylalanine905 (Phe905); and seven are hydrophobic residues: methionine756, methio-
nine801, and methionine909 (Met756, Met801, andMet909), valine760 (Val760), and leucine715,
leucine797, and leucine887 (Leu715, Leu797, and Leu887).
END. The active site in END is formed by the following residues: glutamine725 (Gln725),
cysteine891 (Cys891), glycine722 (Gly722), asparagine719 (Asn19), and arginine766 (Arg766),
which are hydrophilic. The hydrophobic residues are phenylalanine778 (Phe778), tryptophan755
(Trp755), methionine756, methionine759, methionine801, and methionine909 (Met756, Met759,
Met801, and Met909), and leucine715, leucine763, and leucine797 (Leu715, Leu763, and Leu797).
NDTAM. The active site for NDTAM consists of the following residues: leucine718-aspartic
acid719 (Leu718-Asn 719) andmethionine759-valine760 (Met759-Val760). Hydrophilic residues
are glutamine725 (Gln725), arginine766 (Arg766), and cysteine891 (Cys891). Hydrophobic
residues are phenylalanine778 (Phe778), methionine756, methionine801, and methionine909
(Met756, Met801, and Met909), and leucine715, lucine763, leucine797, and leucine887 (Leu715,
Leu763, Leu797, and Leu887).
Most of the residues of the active site of 4OHTAM and END surround the planar core of the
ligand and over the functional group amine. The steric hindrance of this amine group pro-
duces minor binding energy.
When the metabolites bind, there is a conformational change and they are recognized by the
amino acids of the active site. This has to do with the coupling energies. In PR, NDTAM has a
higher amount of binding energy exceeding –9 kcal/mol.
Even when PR is more labile than ER, the binding energies indicate that the receptor is not
sufficiently labile to recognize the metabolites 4OHTAM and END, which present binding
energies lower than –1.5 kcal/mol.
The residues for the metabolites in PR are shown in Figure 5.
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3.3.3. Chemical reactivity
As soon as the most stable structure of the active site of TAM’s metabolites was obtained, an
analysis of the chemical reactivity of progesterone residues was performed by means of the
reactivity descriptors. Results for these calculations are shown in Table 4.
Metabolite Active site EA (eV) I (eV) η (eV) μ = – χ (eV) ω (eV)
4OHTAM Phe905 0.93 6.58 2.82 3.76 2.50
Leu797 0.67 6.86 3.09 3.74 2.36
Leu887 0.43 7.01 3.29 3.72 2.10
Thr894 0.49 6.57 3.04 3.53 2.05
Val760 0.76 6.92 3.08 3.84 2.40
Met756 0.75 6.3 2.77 3.52 2.54
Leu715 0.60 7.02 3.21 3.81 2.26
Gln725 0.70 7.10 3.20 3.90 2.38
Cys891 0.55 6.89 3.17 3.72 2.18
Met801 0.64 6.27 2.82 3.45 2.12
Met909 0.50 6.21 2.85 3.36 1.97
Leu721-Gly722 0.33 7.13 3.73 3.40 1.55
Leu718-Asn719 1.06 7.06 3.00 4.06 2.74
END Arg766 0.21 7.03 3.41 3.62 1.92
Leu763 0.43 6.2 2.89 3.31 1.90
Gly722 0.51 6.25 2.87 3.38 1.99
Met759 0.88 7.74 3.43 4.31 2.71
Gln725 0.70 7.10 3.20 3.90 2.38
Trp755 0.86 5.85 2.50 3.35 2.25
Asn719 0.76 7.16 3.20 3.96 2.45
Leu797 0.67 6.86 3.09 3.74 2.36
Met756 0.75 6.30 2.77 3.52 2.54
Phe778 0.86 6.60 2.87 3.73 2.42
Leu715 0.60 7.02 3.21 3.81 2.26
Cys891 0.55 6.89 3.17 3.72 2.18
Met801 0.64 6.27 2.82 3.45 2.12
Met909 0.73 5.79 2.85 3.26 2.10
NDTAM Leu763 0.35 7.17 3.41 3.76 2.07
Leu797 0.67 6.86 3.09 3.74 2.36
Leu887 0.43 7.01 3.29 3.72 2.10
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The electron affinities of the residues fluctuate from 0.33 eV to 1.06 eV. The highest value of
electron affinity is for the Leu718-Asn719 residue, which is present in the active site of
4OHTAM, NDTAM, and the Met759 residue of END. The ionization potential results show
that the greatest possibility of losing electrons is: Leu721-Gly722 with 7.13 eV in 4OHTAM,
Leu763 with 7.17 eV in NDTAM, and Met759 with 7.74 eV in END.
Chemical hardness, the parameter that measures the resistance to change in the electronic
configuration, exhibited amounts from 2.50 eV to 3.73 eV. In 4OHTAM, the lowest value and
therefore the one that will react more easily in the presence of the metabolites is 2.77 eV for
Met756. For END it is 2.50 eV in Trp755 and 2.61 eV in Met759-Val760. Met801 had a value of
2.82 eV in the NDTAM metabolite.
According to chemical potential, Met759 residue at –4.31 eV presents the highest value in
END. The electronegativity (μ = χ) shows that the Met759 residue has the greatest tendency
to attract electrons at 4.31 eV in END. Electrophilicity ω is the measure of the stabilization
energy when systems become saturated by electrons from the surroundings. In this case in the
active site of 4OHTAM value decreases in the following order: Leu718-Asn719 > Met756 >
Phe905 > Val760 > Gln725 > Leu797 > Leu715 > Cys891 > Met801 > Leu887 > Thr894 > Met909 >
Leu721-Gly722. In END the decreasing order is Met759 > Met756 > Asn719 > Phe778 > Gln725 >
Leu797 > Leu715 > Trp755 > Cys891 > Met801 > Met909 > Gly722 > Arg766 > Leu763 and in
NDTAM the decreasing order is Leu718-Asn719 > Met759-Val760 > Phe778 > Gln725 > Leu797
> Arg766 > Leu715 > Met756 > Cys891 > Met801 > Leu887 > Leu763 > Met909.
3.3.4. Charge transfer descriptor
Considering the high importance of this parameter in the formation of complexes in biological
systems, the highest values in the different metabolites were defined. The charge transfer
between metabolites and PR residues was calculated using Eq. 5. The results show that
Met909 in 4OHTAM, Met909 and Leu763 in END, and Met909, Met756, Arg766, and Leu763
Metabolite Active site EA (eV) I (eV) η (eV) μ = – χ (eV) ω (eV)
Phe778 0.86 6.6 2.87 3.73 2.42
Leu715 0.60 7.02 3.21 3.81 2.26
Arg766 0.78 6.70 2.96 3.74 2.36
Gln725 0.70 7.10 3.20 3.90 2.38
Cys891 0.55 6.89 3.17 3.72 2.18
Met756 0.75 6.30 2.77 3.53 2.24
Met801 0.64 6.27 2.82 3.45 2.12
Met909 0.50 6.21 2.85 3.36 1.97
Met759-Val760 1.05 6.26 2.61 3.65 2.56
Leu718-Asn719 1.06 7.06 3 4.06 2.74
Table 4. Parameters of chemical reactivity of the active site residues of the progesterone receptor.
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in NDTAM act as donor acceptors, namely, these residues are oxidized in the presence of the
metabolites. The remainder of the residues act as electron acceptors. The values are shown in
Table 5.
For 4OHTAM and NDTAM the maxima values are in Leu718-Asp719 with 0.064 and 0.057,
respectively. For END the maxima value is in Met759 with 0.088. Thus, the calculations
Metabolite Residue ΔN
4OHTAM Leu718-Asn719 0.064
Leu721-Gly722 0.002
Phe905 0.037
Leu797 0.033
Leu887 0.03
Thr894 0.014
Val760 0.043
Met756 0.014
Leu715 0.039
Gln725 0.047
Cys891 0.031
Met801 0.007
Met909 0.002
END Arg766 0.027
Leu763 0.001
Gly722 0.006
Met759 0.088
Trp755 0.003
Asn719 0.06
Leu797 0.04
Met756 0.020
Gln725 0.058
Phe778 0.041
Leu715 0.046
Cys891 0.037
Met801 0.013
Met909 0.006
NDTAM Leu763 0.615
Leu797 0.027
Leu887 0.024
Phe778 0.027
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indicate that oxidative damage in the active site decreases in the following order: NDTAM >
END > 4OHTAM.
3.3.5. Electrostatics interactions
An analysis of the hydrogen bond and pi–pi interactions between the active site on PR and
TAM’s metabolites was performed. In the case of 4OHTAM and ENDmetabolites no hydrogen
bonds were generated, nor were there any pi–pi interactions, whereas with NDTAM only a
Metabolite Residue ΔN
Leu715 0.033
Arg766 0.665
Gln725 0.041
Cys891 0.025
Met756 0.669
Met801 0.001
Met909 0.008
Met759-Val760 0.021
Leu718-Asn719 0.057
Table 5. Transfer of charge between metabolites and progesterone receptor residues.
Figure 6. Hydrogen bond (green) at the active site of the progesterone receptor with the NDTAM metabolite.
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hydrogen bond (C=O----H-N) was formed between the Asn719 residue and the amino group.
The unique electrostatic interaction is shown with green dots in Figure 6. Also, it was found
that the rule of five by Lipinski et al. [52, 53] was fulfilled.
4. Conclusions
In this chapter the molecular docking of ER and PR with TAM’s metabolites, 4OHTAM,
NDTAM, and NDTAM, was analyzed. The amino acids sequence of the active site for each
ligand–macromolecule complex was examined. The residues that constituted each active site
were analyzed separately to find the charge transfer parameter, the hydrogen bond, and the
pi–pi interaction between the ligand and the receptor.
According to the binding energy obtained from docking, ER has greater stability than PR with
the metabolites analyzed. However, in both cases there is a coupling between the receptor and
the ligand, even when two of the binding energies in PR–ligand coupling are very small.
This coupling plays an important part in avoiding the transcription factor cascade reported by
Leehy et al. [54].
This information agrees with the results of the chemical reactivity parameters, where it was
found that the average of the chemical hardness values are lowest in active site residues of ER
than in PR.
The charge transfer descriptor shows that TAM’s metabolites mostly act as electron acceptors
in their interaction with the hormone receptors. The hydrogen bonds in ER with END agree
with the highest binding energy of this ligand. There are two hydrogen bonds, one pi–pi
interaction, and a ∆N of –0.086. While in PR, there is only one hydrogen bond with NDTAM
and the value of ∆N is –0.057.
This work described the successful combination of the methods of molecular mechanics and
electronic structure. It also explored the different conformational spaces and binding modes
that allow smaller systems to work with them at the electronic level.
In addition to the above a significant conclusion is that the molecular modeling and simula-
tions are an important improvement tool for any laboratory in many industries. Currently,
many sectors are moving toward using more modeling and simulations in their laboratories.
As Bernard Charlès, Dassault Systèmes CEO, states: “digitalization will mean big changes for
everyday lab activities down the road.” Two key solutions for all industries (such as pharma-
ceutical, chemical, life sciences, energy, and consumer goods) are collaboration and the ability
to predict using simulation and modeling [55].
Patrick Bultinck et al. in their preface to the book Computational Medicinal Chemistry for Drug
Discovery [21] wrote: “Nowadays, one can safely state that the computational chemist has
become a respectable member of a drug design team.” And we can add that the docking tool
is essential for most techniques for structure-based drug design.
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